FTC (US Federal Trade Commission) blocks Abbott's deal with Alza over antitrust concerns
This article was originally published in Clinica
Executive Summary
Abbott's proposed $7.3 billion acquisition of drug delivery company Alza has collapsed after the two companies failed to satisfy the US Federal Trade Commission's antitrust concerns. The development is the second serious blow for Abbott in six weeks, following its $100 million settlement with the FDA over manufacturing issues.